Post Date December, 03 2023
Aspirin is safe and effective in preventing the occurrence of acute urinary retention in patients with benign prostatic hyperplasia, which greatly reduces the risk of surgical treatment for patients with benign prostatic hyperplasia. However, aspirin does not reduce the size of the prostate in patients with BPH, nor does it improve maximum urinary flow rate and disease symptoms.
Aspirin reduces the incidence of acute urinary retention in patients with benign prostatic hyperplasia because it reduces the incidence of prostate infarction. The patients with BPH are elderly men, whose acute urinary retention is closely related to acute prostate infarction, and the most common cause of acute prostate infarction is thrombosis caused by arterial atherosclerosis. Aspirin, a commonly used antiplatelet agglutination drug, can prevent and treat this acute prostate infarction, thereby reducing the incidence of acute urinary retention in patients. However, the mechanism of action of aspirin does not include reducing prostate volume, improving maximum urinary flow rate, and disease symptoms.
Although acute urinary retention itself will not lead to serious consequences, most patients with BPH are elderly, and are prone to be associated with hypertension, diabetes, coronary heart disease and other basic diseases. Acute urinary retention may induce the occurrence of acute events of such diseases. Aspirin itself has positive significance in reducing the incidence of such acute cardiovascular events.
(Intern Editor: Xie Yunsheng)
